Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease Undergoing Dialysis
NCT07619820Phase 1Recruiting
- Sponsor
- CSL Limited
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Kidney disease comparing CSL300 (Clazakizumab) with Placebo (2 arms). Primary endpoints: Area Under the Concentration-time Curve of CSL300 Over 1 Dosing Interval After Multiple Doses at Day 113 and Trough Concentration at Steady State. Started Jun 2026; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
Kidney disease
Beyond the preview
Go deeper on NCT07619820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619820.